Capsule based inhalers are used for the delivery of medicines through the lungs. Amongst all the inhalers, capsule-based inhalers are the most commonly used inhalers for the treatment of pulmonary diseases. Capsule based inhalers come under the category of dry powder inhalers. Capsule based inhalation systems are very easy to use and they are very much effective for chronic pulmonary diseases.
Capsule-based inhalation systems consist of a chamber, in which a capsule is stored, the capsule is either broken into a powdered form or it is inhaled by the patient. Capsule based inhalation systems are mainly used for the treatment of bronchitis or asthma.
There can be many forecast factors, which can boost the growth of capsule-based inhalation systems market. Increasing prevalence of chronic pulmonary diseases such as asthma, bronchitis, and obstructive pulmonary disorder, is expected to increase the growth of capsule-based inhalation market in the forecast period. Other factors such as the innovation of new and advanced inhalers can be responsible for the growth of capsule-based inhalation market.
Leading manufacturers of capsule-based inhalers are focusing on the new product development and mergers & acquisitions, which can boost the growth of capsule-based inhalation market.
Growing prevalence of chronic pulmonary disorders is one of the major factors, which is responsible for the growth of capsule-based inhalation market. Capsule Based inhalers are cost-effective and portable, which can increase their demand and can boost the Capsule Based inhalation market. Increasing geriatric population is another important factor which is responsible for the growth of Capsule Based inhalation market. Technological advancements lead to the introduction of new advanced inhalers, which can boost the overall growth of the Capsule Based inhalation market. Various other factors, such as the increasing number of hospitals, increasing healthcare awareness, increasing air pollution, increasing research and developmental activities, etc. can increase the growth of Capsule Based inhalation market. The capsule-based inhalers reduce the cost of the treatment of respiratory disorders, which is a major driver of capsule-based inhalation market.
The side effects caused by Capsule Based inhalers can restrain the growth of Capsule Based inhalation market. There can be some technical issues associated with capsule based inhalation systems, which can affect its effectiveness. This factor can also hinder the growth of the capsule-based inhalation market.
The Capsule Based Inhalation market is segmented by Indication, Distribution channel and Geography.
Based on indication, the capsule-based inhalation market has been segmented into Asthma, obstructive pulmonary disease, bronchitis, and other chronic pulmonary diseases. Asthma is expected to hold the largest revenue share in the capsule based inhalation market. Based on the distribution channel, the capsule-based inhalation market has been studied by dividing it into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. Hospital pharmacies and drug stores are expected to hold the maximum revenue share in the capsule based inhalation market.
On the basis of geography, Capsule Based Inhalation market is segmented into a few key regions i.e. North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa. North America is projected to hold the largest revenue shares in the global Capsule Based Inhalation market primarily due to the presence of technological advancement in the field of healthcare and enhanced healthcare infrastructure. Europe is expected to show a high revenue share in the Capsule Based Inhalation market due to increasing population and increasing healthcare awareness. The Asia Pacific is expected to hold a large revenue share in the capsule based inhalation market because of the increasing population and increasing number of hospital pharmacies and drug stores.
Some of the key players present in global Capsule Based Inhalation market are H&T Presspart Manufacturing Ltd., Aptar Pharma, Vectura Group plc, Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca plc, Hovione, Iconovo AB, GlaxoSmithKline plc and others.
The report covers exhaustive analysis on:
Regional analysis includes